369 related articles for article (PubMed ID: 22958493)
41. Selective phosphodiesterase-5 (PDE-5) inhibitor vardenafil ameliorates renal damage in type 1 diabetic rats by restoring cyclic 3',5' guanosine monophosphate (cGMP) level in podocytes.
Fang L; Radovits T; Szabó G; Mózes MM; Rosivall L; Kökény G
Nephrol Dial Transplant; 2013 Jul; 28(7):1751-61. PubMed ID: 23203993
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of lncRNA-PAX8-AS1-N directly associated with VEGF/TGF-β1/8-OhdG enhances podocyte apoptosis in diabetic nephropathy.
Shen Y; Tong ZW; Zhou Y; Sun Y; Xie Y; Li R; Liu H
Eur Rev Med Pharmacol Sci; 2020 Jun; 24(12):6864-6872. PubMed ID: 32633379
[TBL] [Abstract][Full Text] [Related]
43. Effects of High Glucose and Lipotoxicity on Diabetic Podocytes.
Nakamichi R; Hayashi K; Itoh H
Nutrients; 2021 Jan; 13(1):. PubMed ID: 33467659
[TBL] [Abstract][Full Text] [Related]
44. Klotho ameliorates diabetic nephropathy by activating Nrf2 signaling pathway in podocytes.
Xing L; Guo H; Meng S; Zhu B; Fang J; Huang J; Chen J; Wang Y; Wang L; Yao X; Wang H
Biochem Biophys Res Commun; 2021 Jan; 534():450-456. PubMed ID: 33256980
[TBL] [Abstract][Full Text] [Related]
45. Semaphorin3a promotes advanced diabetic nephropathy.
Aggarwal PK; Veron D; Thomas DB; Siegel D; Moeckel G; Kashgarian M; Tufro A
Diabetes; 2015 May; 64(5):1743-59. PubMed ID: 25475434
[TBL] [Abstract][Full Text] [Related]
46. Wnt signaling and podocyte dysfunction in diabetic nephropathy.
Bose M; Almas S; Prabhakar S
J Investig Med; 2017 Dec; 65(8):1093-1101. PubMed ID: 28935636
[TBL] [Abstract][Full Text] [Related]
47. Podocytes as a target of prorenin in diabetes.
Sakoda M; Itoh H; Ichihara A
Curr Diabetes Rev; 2011 Jan; 7(1):17-21. PubMed ID: 21067509
[TBL] [Abstract][Full Text] [Related]
48. Cellular and molecular mechanisms of proteinuria in diabetic nephropathy.
Wolf G; Ziyadeh FN
Nephron Physiol; 2007; 106(2):p26-31. PubMed ID: 17570945
[TBL] [Abstract][Full Text] [Related]
49. Regeneration of glomerular metabolism and function by podocyte pyruvate kinase M2 in diabetic nephropathy.
Fu J; Shinjo T; Li Q; St-Louis R; Park K; Yu MG; Yokomizo H; Simao F; Huang Q; Wu IH; King GL
JCI Insight; 2022 Mar; 7(5):. PubMed ID: 35133981
[TBL] [Abstract][Full Text] [Related]
50. Vitamin D3 ameliorates podocyte injury through the nephrin signalling pathway.
Trohatou O; Tsilibary EF; Charonis A; Iatrou C; Drossopoulou G
J Cell Mol Med; 2017 Oct; 21(10):2599-2609. PubMed ID: 28664547
[TBL] [Abstract][Full Text] [Related]
51. Antioxidants ameliorate the expression of vascular endothelial growth factor mediated by protein kinase C in diabetic podocytes.
Lee EY; Chung CH; Kim JH; Joung HJ; Hong SY
Nephrol Dial Transplant; 2006 Jun; 21(6):1496-503. PubMed ID: 16484238
[TBL] [Abstract][Full Text] [Related]
52. Growth hormone induces Notch1 signaling in podocytes and contributes to proteinuria in diabetic nephropathy.
Nishad R; Mukhi D; Tahaseen SV; Mungamuri SK; Pasupulati AK
J Biol Chem; 2019 Nov; 294(44):16109-16122. PubMed ID: 31511328
[TBL] [Abstract][Full Text] [Related]
53. Hyperglycemia to nephropathy via transforming growth factor beta.
Garud MS; Kulkarni YA
Curr Diabetes Rev; 2014 May; 10(3):182-9. PubMed ID: 24919657
[TBL] [Abstract][Full Text] [Related]
54. Mangiferin prevents diabetic nephropathy progression and protects podocyte function via autophagy in diabetic rat glomeruli.
Wang X; Gao L; Lin H; Song J; Wang J; Yin Y; Zhao J; Xu X; Li Z; Li L
Eur J Pharmacol; 2018 Apr; 824():170-178. PubMed ID: 29444469
[TBL] [Abstract][Full Text] [Related]
55. Protein tyrosine phosphatase 1B deficiency in podocytes mitigates hyperglycemia-induced renal injury.
Ito Y; Hsu MF; Bettaieb A; Koike S; Mello A; Calvo-Rubio M; Villalba JM; Haj FG
Metabolism; 2017 Nov; 76():56-69. PubMed ID: 28987240
[TBL] [Abstract][Full Text] [Related]
56. Soluble Flt-1 gene therapy ameliorates albuminuria but accelerates tubulointerstitial injury in diabetic mice.
Kosugi T; Nakayama T; Li Q; Chiodo VA; Zhang L; Campbell-Thompson M; Grant M; Croker BP; Nakagawa T
Am J Physiol Renal Physiol; 2010 Mar; 298(3):F609-16. PubMed ID: 20015944
[TBL] [Abstract][Full Text] [Related]
57. Protein phosphatases and podocyte function.
Geraldes P
Curr Opin Nephrol Hypertens; 2018 Jan; 27(1):49-55. PubMed ID: 29068796
[TBL] [Abstract][Full Text] [Related]
58. MYDGF attenuates podocyte injury and proteinuria by activating Akt/BAD signal pathway in mice with diabetic kidney disease.
He M; Li Y; Wang L; Guo B; Mei W; Zhu B; Zhang J; Ding Y; Meng B; Zhang L; Xiang L; Dong J; Liu M; Xiang L; Xiang G
Diabetologia; 2020 Sep; 63(9):1916-1931. PubMed ID: 32588068
[TBL] [Abstract][Full Text] [Related]
59. FPS-ZM1 and valsartan combination protects better against glomerular filtration barrier damage in streptozotocin-induced diabetic rats.
Sanajou D; Ghorbani Haghjo A; Argani H; Roshangar L; Ahmad SNS; Jigheh ZA; Aslani S; Panah F; Rashedi J; Mesgari Abbasi M
J Physiol Biochem; 2018 Aug; 74(3):467-478. PubMed ID: 29948786
[TBL] [Abstract][Full Text] [Related]
60. Epigenetic Regulation Through SIRT1 in Podocytes.
Nakatani Y; Inagi R
Curr Hypertens Rev; 2016; 12(2):89-94. PubMed ID: 26931472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
